Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 1996The Journal of Immunology

Liver NK1.1+ CD4+ αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis

View Full Paper
Ask AI
Bookmark
Share

Authors

KTKaori TakedaTohoku UniversitySSShuji SekiHiroshima UniversityKOK. OGASAWARAHokkaido University of Science

Discussion

Loading...

Member takes

Implication

Randomized trial demonstrates that IL-12-activated T cells inhibit metastasis in liver and lung, suggesting a promising therapeutic approach.

Key Points

  • This research aims to investigate the role of IL-12-activated liver NK1high TCRint cells in inhibiting tumor metastasis.
  • Administered IL-12 to activate liver NK1+ TCRint cells.
  • Conducted cytotoxicity assays and cell transfers to tumor-preinjected mice.
  • Analyzed the effects of T cell depletion on metastasis inhibition.
  • IL-12 administration significantly enhanced NK1high TCRint cells' cytotoxicity against metastases.
  • Transfer of IL-12-stimulated hepatic mononuclear cells inhibited lung and liver metastases.
  • Depletion of NK1+, CD3+, or CD4+ cells prior to transfer abrogated metastasis inhibition.

Cite This Study

Takeda et al. (1996) studied this question.

synapsesocial.com/papers/6a6cde31febe604dd7079ccfhttps://doi.org/10.4049/jimmunol.156.9.3366
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1RECRUITMENT OF HEPATIC NATURAL KILLER CELLS BY EXOGENOUS CYTOKINE THERAPY WITH EITHER IL-2 OR IL-122002
  2. 2Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors2012 · 421 citations
  3. 3Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treats low-burden metastases2024
  4. 4Abstract 1386: CD1d-restricted iNKT cells promote liver metastasis from colon cancer2024
  5. 5Syngeneic natural killer cell therapy activates dendritic and T cells in metastatic lungs and effectively treat low-burden metastases2024